Roy M. Punnoose

Array ( [id] => 20246739 [patent_doc_number] => 20250295608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-25 [patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS [patent_app_type] => utility [patent_app_number] => 19/079373 [patent_app_country] => US [patent_app_date] => 2025-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19079373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19862250 [patent_doc_number] => 20250101036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/956941 [patent_app_country] => US [patent_app_date] => 2024-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18956941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846735 [patent_doc_number] => 20250092086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => CELASTROL SALTS, CRYSTALLINE FORMS, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/945768 [patent_app_country] => US [patent_app_date] => 2024-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18945768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599424 [patent_doc_number] => 20240390304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => Oral Solutions Comprising Lisdexamfetamine Salts [patent_app_type] => utility [patent_app_number] => 18/792999 [patent_app_country] => US [patent_app_date] => 2024-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18792999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586309 [patent_doc_number] => 20240383866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 [patent_app_type] => utility [patent_app_number] => 18/783231 [patent_app_country] => US [patent_app_date] => 2024-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18783231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510466 [patent_doc_number] => 20240342152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => Method of Treatment [patent_app_type] => utility [patent_app_number] => 18/677361 [patent_app_country] => US [patent_app_date] => 2024-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3631 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18677361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526540 [patent_doc_number] => 20240350442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/653106 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19921794 [patent_doc_number] => 12296053 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Nanomaterials comprising triols [patent_app_type] => utility [patent_app_number] => 18/611561 [patent_app_country] => US [patent_app_date] => 2024-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 42486 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19594169 [patent_doc_number] => 12151999 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-26 [patent_title] => Small molecule compounds having naphthylamine structure and application thereof [patent_app_type] => utility [patent_app_number] => 18/606722 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 14 [patent_no_of_words] => 14857 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 536 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19629626 [patent_doc_number] => 20240408075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/603554 [patent_app_country] => US [patent_app_date] => 2024-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18603554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246762 [patent_doc_number] => 20240197746 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => COMBINATION THERAPY WITH A MEK INHIBITOR AND A SRC INHIBITOR FOR THE TREATMENT OF COLORECTAL CANCER [patent_app_type] => utility [patent_app_number] => 18/589576 [patent_app_country] => US [patent_app_date] => 2024-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18589576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19579834 [patent_doc_number] => 12145930 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-11-19 [patent_title] => 4-thiazolidinone derivatives as EGFR inhibitors for anti-tumor activity [patent_app_type] => utility [patent_app_number] => 18/443136 [patent_app_country] => US [patent_app_date] => 2024-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9980 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343500 [patent_doc_number] => 20240252463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => METHODS OF TREATING FIBROTIC PATHOLOGIES [patent_app_type] => utility [patent_app_number] => 18/422541 [patent_app_country] => US [patent_app_date] => 2024-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18422541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541667 [patent_doc_number] => 20240358703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA [patent_app_type] => utility [patent_app_number] => 18/418061 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18418061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201427 [patent_doc_number] => 20240173326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/405638 [patent_app_country] => US [patent_app_date] => 2024-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18405638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19651237 [patent_doc_number] => 12173005 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-24 [patent_title] => Pyrimido[1',6':1,5]pyrazolo[4,3-b][1,7]naphthyridine compounds as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/393644 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9602 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638062 [patent_doc_number] => 12168662 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-17 [patent_title] => Pyrido[4',3':4,5]pyrrolo[2,3-c][2,7]naphthyridines compounds as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/542368 [patent_app_country] => US [patent_app_date] => 2023-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8761 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18542368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083029 [patent_doc_number] => 20240109830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => CANNABIS EXTRACTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/516260 [patent_app_country] => US [patent_app_date] => 2023-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29750 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18516260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19081825 [patent_doc_number] => 20240108626 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/501729 [patent_app_country] => US [patent_app_date] => 2023-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860174 [patent_doc_number] => 20230414608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => USE OF ATR AND CHK1 INHIBITOR COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/343285 [patent_app_country] => US [patent_app_date] => 2023-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18343285 [rel_patent_id] =>[rel_patent_doc_number] =>)